Share
June 27, 2021 The University of Oxford has announced that it has begun to inject some volunteers with a vaccine developed with Astrazeneca against the South African variant of Coronavirus Beta as part of some clinical studies to measure its effectiveness.
In a statement, the university states that the trial involves 2,250 participants recruited in the UK, South Africa, Brazil, and Poland as part of phase II and III clinical trials in humans. Participants also included people who received both doses of the Astrazeneca or Pfizer vaccine, but also patients not yet immunized. The vaccine uses the same so-called 'viral vector' technology currently used against Covid-19 around the world.
"Testing the booster doses of existing vaccines and vaccines against new variants is important to ensure we are as prepared as possible to keep up with the Coronavirus pandemic, should their use prove necessary," said Professor Andrew Pollard. , director of the Oxford vaccine group. Provisional data from these clinical trials are expected by the end of the year.